Table 1

Association between METs achieved and incident diabetes among participants without diabetes at baseline according to strata of BMI <30 or ≥30 kg/m2

Model 1Model 2Model 3
BMI <30 kg/m2 (N = 7,574)
 Categories of fitness
  <61.0 (reference)1.0 (reference)1.0 (reference)
  6–91.07 (0.90, 1.26)1.09 (0.92, 1.29)1.09 (0.92, 1.29)
  10–110.88 (0.74, 1.04)0.93 (0.78, 1.11)0.94 (0.78, 1.12)
   ≥120.65 (0.53, 0.80)0.72 (0.58, 0.89)0.73 (0.59, 0.91)
  P trend across categories as ordinal variable<0.001<0.0010.001
 METs per 1 unit0.95 (0.93, 0.97)0.96 (0.94, 0.98)0.96 (0.94, 0.98)
  P value<0.001<0.001<0.001
BMI ≥30 kg/m2 (N = 4,176)
 Categories of fitness
  <61.0 (reference)1.0 (reference)1.0 (reference)
  6–90.83 (0.71, 0.97)0.83 (0.71, 0.97)0.88 (0.75, 1.03)
  10–110.75 (0.63, 0.89)0.76 (0.64, 0.91)0.84 (0.70, 1.01)
   ≥120.46 (0.35, 0.59)0.49 (0.38, 0.64)0.56 (0.42, 0.73)
  P trend across categories as ordinal variable<0.001<0.001<0.001
 METs per 1 unit0.94 (0.92, 0.96)0.94 (0.92, 0.97)0.96 (0.93, 0.98)
  P value<0.001<0.0010.001
  • Data are hazard ratio (95% CI). P value for the interaction comparing the association of METs achieved (METs per 1 unit) with incident diabetes (model 3) across strata of BMI (<30 vs. ≥30 kg/m2) was 0.06. Model 1: adjusted for age, sex, race. Model 2: model 1 plus history of hypertension, hypertension medication use, ACE inhibitor use, angiotensin II receptor blocker use, β-blocker use, diuretic use, history of hyperlipidemia, lipid-lowering medication use, statin use, history of obesity, family history of coronary heart disease, current smoking status, sedentary lifestyle, treated pulmonary disease, depression medication use, and indication for stress testing. Model 3: model 2 plus BMI.